Nyrada, Inc. operates as a pre-clinical stage, drug development company. It specializes in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. The company was founded by Graham Kelly and Ian Dixon on August 29, 2017 and is headquartered in Gordon, Australia.
ASX